Welcome to our dedicated page for Soleno Therapeutics news (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.
News about Soleno Therapeutics, Inc. (NASDAQ: SLNO) centers on its work as a biopharmaceutical company developing and commercializing novel therapeutics for rare diseases, with a primary focus on Prader-Willi syndrome (PWS) and hyperphagia. Company press releases highlight clinical, regulatory, commercial, and corporate developments related to its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets.
Readers following SLNO news can find updates on VYKAT XR, a once-daily oral treatment indicated for hyperphagia in adults and pediatric patients 4 years of age and older with PWS. News items include details of the Phase 3 clinical program, such as the randomized withdrawal study published in the Journal of Clinical Endocrinology and Metabolism, which Soleno reports supported FDA approval as the first treatment for hyperphagia in people living with PWS.
Soleno’s news flow also covers financial results and launch metrics for VYKAT XR, including product revenue from U.S. sales, patient start forms, prescriber adoption, coverage levels, and commentary on achieving profitability and positive cash flow. Investors can track announcements about preliminary and full-quarter results, conference call schedules, and corporate presentations.
Additional news topics include capital allocation and corporate actions, such as the Board-authorized $100 million accelerated share repurchase agreement, amendments to loan facilities, and Board and Audit Committee changes. The company also issues communications on safety and regulatory matters, including an 8-K describing a serious adverse event reported in the FDA’s FAERS database and Soleno’s assessment of that case.
For those monitoring SLNO, this news stream provides insight into Soleno’s rare disease strategy, the commercial trajectory of VYKAT XR in PWS, and key corporate and regulatory milestones disclosed through press releases and SEC-referenced communications.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) has priced a public offering of 40 million shares at $0.25 each, with 20 million pre-funded warrants at $0.24, totaling gross proceeds of approximately $14.8 million. The offering includes accompanying warrants exercisable at $0.30 per share. Proceeds will fund research on DCCR tablets for Prader-Willi Syndrome and cover general corporate purposes. The offering is set to close around March 31, 2022, subject to customary conditions. Oppenheimer & Co. Inc. is the sole book-running manager.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced its intention to offer and sell shares of common stock and pre-funded warrants in an underwritten public offering. Each share or pre-funded warrant will be sold with an exercisable common warrant. The offering's completion and terms are subject to market conditions. Proceeds will primarily fund research and development of the DCCR tablets for Prader-Willi Syndrome, along with general corporate purposes. Oppenheimer & Co. Inc. is the sole book-running manager for this offering.
Soleno Therapeutics (NASDAQ: SLNO) announced that Running for Research - Prader-Willi Syndrome will fund a clinical study of Diazoxide Choline Extended-Release (DCCR) for early-phase Prader-Willi Syndrome (PWS) patients. The multi-center trial will involve 40 subjects at four U.S. institutions, aiming to assess DCCR's effectiveness in preventing hyperphagia progression. Initial data from ongoing Phase 3 trials indicate potential benefits of DCCR. Running for Research exceeded their funding goals significantly, reflecting strong community support for the study.
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced its CEO Anish Bhatnagar will present a corporate overview at the BIO CEO & Investor Conference on February 15, 2022, at 2:15 PM Eastern Time. The company focuses on developing novel therapeutics for rare diseases. Its lead candidate, DCCR extended-release tablets, is in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS). For more information, visit www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO) announced the grant of inducement awards to new executives, Scott Madsen and Charles Horn, each receiving non-qualified stock options for 70,000 shares. The options have an exercise price of $0.34 per share, equal to the stock's closing price on January 28, 2022. The options will vest over four years, with 25% vesting each year upon continued employment. Soleno is focused on developing therapeutics for rare diseases, with its lead product, DCCR, in Phase 3 clinical trials for Prader-Willi Syndrome.
Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company, updated on its progress with the FDA regarding its DCCR (diazoxide choline) extended-release tablets for treating Prader-Willi syndrome (PWS). Following a Type C meeting on December 21, 2021, the FDA showed receptiveness to a study design utilizing current participants from the ongoing Study C602 to gather additional clinical data necessary for a New Drug Application (NDA). The company plans to submit a proposal for this study soon. Currently, there are no approved therapies addressing the symptoms of PWS, underscoring the significance of Soleno’s work.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced the participation of CEO Anish Bhatnagar in a panel discussion at the LifeSci Partners 11th Annual Corporate Access Event on January 6, 2022. The panel, titled Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders, will take place at 2:00 PM ET. A live webcast is available at this link, and a replay can be accessed on the company’s website. Soleno is focused on developing treatments for rare diseases, notably evaluating its lead candidate for Prader-Willi Syndrome.
Soleno Therapeutics (NASDAQ: SLNO) announced the grant of stock options to new VP of Clinical Development, Michael Woloschak, in compliance with Nasdaq rules.
The non-qualified stock option is for 75,000 shares at an exercise price of $0.763, equal to Soleno's stock closing price on November 16, 2021. The options vest over four years, beginning with 1/4 on the one-year anniversary of September 27, 2021, and subsequently 1/48 each month, contingent on continued employment.
Soleno focuses on developing therapies for rare diseases, including its candidate for Prader-Willi Syndrome.
Soleno Therapeutics (SLNO) reported financial results for Q3 and nine months ended September 30, 2021. The company is developing DCCR, a treatment for Prader-Willi syndrome (PWS), with promising data from its open-label extension study, C602. Significant improvements were reported in hyperphagia and PWS-related behaviors after 52 weeks of treatment. Financially, R&D expenses were $5.0 million for Q3 compared to $4.8 million last year. The net loss for Q3 was $8.1 million, slightly down from $8.5 million in 2020. As of September 30, 2021, cash and equivalents totaled approximately $28.2 million.
Soleno Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: SLNO), announced that CEO Anish Bhatnagar will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 2:40 PM ET.
A live audio webcast and replay can be accessed on the company’s website. Soleno focuses on developing therapeutics for rare diseases, particularly DCCR extended-release tablets for treating Prader-Willi Syndrome, currently in a Phase 3 clinical program.